Tasigna gets Swiss nod as first-line drug

Novartis' Tasigna won its first European approval as a first-line treatment when Swiss authorities green-lighted the blood cancer drug after a fast-track review. Novartis release | Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…